Antibody-mediated protection against MERS-CoV in the murine model

R.R.C. New, B.D. Moore, W. Butcher, R. Mahood, M.S. Lever, S. Smither, L. O'Brien, S.A. Weller, M. Bayliss, L.C.D. Gibson, C. Macleod, M. Bogus, R. Harvey, N. Almond, E.D. Williamson

Research output: Contribution to journalArticle

Abstract

Murine antisera with neutralising activity for the coronavirus causative of Middle East respiratory syndrome (MERS) were induced by immunisation of Balb/c mice with the receptor binding domain (RBD) of the viral Spike protein. The murine antisera induced were fully-neutralising in vitro for two separate clinical strains of the MERS coronavirus (MERS-CoV). To test the neutralising capacity of these antisera in vivo, susceptibility to MERS-CoV was induced in naive recipient Balb/c mice by the administration of an adenovirus vector expressing the human DPP4 receptor (Ad5-hDPP4) for MERS-CoV, prior to the passive transfer of the RBD-specific murine antisera to the transduced mice. Subsequent challenge of the recipient transduced mice by the intra-nasal route with a clinical isolate of the MERS-CoV resulted in a significantly reduced viral load in their lungs, compared with transduced mice receiving a negative control antibody. The murine antisera used were derived from mice which had been primed sub-cutaneously with a recombinant fusion of RBD with a human IgG Fc tag (RBD-Fc), adsorbed to calcium phosphate microcrystals and then boosted by the oral route with the same fusion protein in reverse micelles. The data gained indicate that this dual-route vaccination with novel formulations of the RBD-Fc, induced systemic and mucosal anti-viral immunity with demonstrated in vitro and in vivo neutralisation capacity for clinical strains of MERS-CoV.

LanguageEnglish
Pages4094-4102
Number of pages9
JournalVaccine
Volume37
Issue number30
Early online date6 Jun 2019
DOIs
Publication statusPublished - 9 Jul 2019

Fingerprint

Coronavirus Infections
Middle East
animal models
Immune Sera
antibodies
Antibodies
mice
antiserum
neutralization
receptors
Fc Receptors
Micelles
Viral Proteins
Viral Load
Nose
Adenoviridae
Immunity
Immunization
Vaccination
Immunoglobulin G

Keywords

  • coronavirus
  • MERS
  • mucosal immunity
  • neutralising antibody
  • novel vaccine formulation
  • respiratory infection
  • systemic immunity
  • vaccination

Cite this

New, R. R. C., Moore, B. D., Butcher, W., Mahood, R., Lever, M. S., Smither, S., ... Williamson, E. D. (2019). Antibody-mediated protection against MERS-CoV in the murine model. Vaccine, 37(30), 4094-4102. https://doi.org/10.1016/j.vaccine.2019.05.074
New, R.R.C. ; Moore, B.D. ; Butcher, W. ; Mahood, R. ; Lever, M.S. ; Smither, S. ; O'Brien, L. ; Weller, S.A. ; Bayliss, M. ; Gibson, L.C.D. ; Macleod, C. ; Bogus, M. ; Harvey, R. ; Almond, N. ; Williamson, E.D. / Antibody-mediated protection against MERS-CoV in the murine model. In: Vaccine. 2019 ; Vol. 37, No. 30. pp. 4094-4102.
@article{e7970ca3ec554d0b9165592025d536e7,
title = "Antibody-mediated protection against MERS-CoV in the murine model",
abstract = "Murine antisera with neutralising activity for the coronavirus causative of Middle East respiratory syndrome (MERS) were induced by immunisation of Balb/c mice with the receptor binding domain (RBD) of the viral Spike protein. The murine antisera induced were fully-neutralising in vitro for two separate clinical strains of the MERS coronavirus (MERS-CoV). To test the neutralising capacity of these antisera in vivo, susceptibility to MERS-CoV was induced in naive recipient Balb/c mice by the administration of an adenovirus vector expressing the human DPP4 receptor (Ad5-hDPP4) for MERS-CoV, prior to the passive transfer of the RBD-specific murine antisera to the transduced mice. Subsequent challenge of the recipient transduced mice by the intra-nasal route with a clinical isolate of the MERS-CoV resulted in a significantly reduced viral load in their lungs, compared with transduced mice receiving a negative control antibody. The murine antisera used were derived from mice which had been primed sub-cutaneously with a recombinant fusion of RBD with a human IgG Fc tag (RBD-Fc), adsorbed to calcium phosphate microcrystals and then boosted by the oral route with the same fusion protein in reverse micelles. The data gained indicate that this dual-route vaccination with novel formulations of the RBD-Fc, induced systemic and mucosal anti-viral immunity with demonstrated in vitro and in vivo neutralisation capacity for clinical strains of MERS-CoV.",
keywords = "coronavirus, MERS, mucosal immunity, neutralising antibody, novel vaccine formulation, respiratory infection, systemic immunity, vaccination",
author = "R.R.C. New and B.D. Moore and W. Butcher and R. Mahood and M.S. Lever and S. Smither and L. O'Brien and S.A. Weller and M. Bayliss and L.C.D. Gibson and C. Macleod and M. Bogus and R. Harvey and N. Almond and E.D. Williamson",
year = "2019",
month = "7",
day = "9",
doi = "10.1016/j.vaccine.2019.05.074",
language = "English",
volume = "37",
pages = "4094--4102",
journal = "Vaccine",
issn = "0264-410X",
number = "30",

}

New, RRC, Moore, BD, Butcher, W, Mahood, R, Lever, MS, Smither, S, O'Brien, L, Weller, SA, Bayliss, M, Gibson, LCD, Macleod, C, Bogus, M, Harvey, R, Almond, N & Williamson, ED 2019, 'Antibody-mediated protection against MERS-CoV in the murine model' Vaccine, vol. 37, no. 30, pp. 4094-4102. https://doi.org/10.1016/j.vaccine.2019.05.074

Antibody-mediated protection against MERS-CoV in the murine model. / New, R.R.C.; Moore, B.D.; Butcher, W.; Mahood, R.; Lever, M.S.; Smither, S.; O'Brien, L.; Weller, S.A.; Bayliss, M.; Gibson, L.C.D.; Macleod, C.; Bogus, M.; Harvey, R.; Almond, N.; Williamson, E.D.

In: Vaccine, Vol. 37, No. 30, 09.07.2019, p. 4094-4102.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antibody-mediated protection against MERS-CoV in the murine model

AU - New, R.R.C.

AU - Moore, B.D.

AU - Butcher, W.

AU - Mahood, R.

AU - Lever, M.S.

AU - Smither, S.

AU - O'Brien, L.

AU - Weller, S.A.

AU - Bayliss, M.

AU - Gibson, L.C.D.

AU - Macleod, C.

AU - Bogus, M.

AU - Harvey, R.

AU - Almond, N.

AU - Williamson, E.D.

PY - 2019/7/9

Y1 - 2019/7/9

N2 - Murine antisera with neutralising activity for the coronavirus causative of Middle East respiratory syndrome (MERS) were induced by immunisation of Balb/c mice with the receptor binding domain (RBD) of the viral Spike protein. The murine antisera induced were fully-neutralising in vitro for two separate clinical strains of the MERS coronavirus (MERS-CoV). To test the neutralising capacity of these antisera in vivo, susceptibility to MERS-CoV was induced in naive recipient Balb/c mice by the administration of an adenovirus vector expressing the human DPP4 receptor (Ad5-hDPP4) for MERS-CoV, prior to the passive transfer of the RBD-specific murine antisera to the transduced mice. Subsequent challenge of the recipient transduced mice by the intra-nasal route with a clinical isolate of the MERS-CoV resulted in a significantly reduced viral load in their lungs, compared with transduced mice receiving a negative control antibody. The murine antisera used were derived from mice which had been primed sub-cutaneously with a recombinant fusion of RBD with a human IgG Fc tag (RBD-Fc), adsorbed to calcium phosphate microcrystals and then boosted by the oral route with the same fusion protein in reverse micelles. The data gained indicate that this dual-route vaccination with novel formulations of the RBD-Fc, induced systemic and mucosal anti-viral immunity with demonstrated in vitro and in vivo neutralisation capacity for clinical strains of MERS-CoV.

AB - Murine antisera with neutralising activity for the coronavirus causative of Middle East respiratory syndrome (MERS) were induced by immunisation of Balb/c mice with the receptor binding domain (RBD) of the viral Spike protein. The murine antisera induced were fully-neutralising in vitro for two separate clinical strains of the MERS coronavirus (MERS-CoV). To test the neutralising capacity of these antisera in vivo, susceptibility to MERS-CoV was induced in naive recipient Balb/c mice by the administration of an adenovirus vector expressing the human DPP4 receptor (Ad5-hDPP4) for MERS-CoV, prior to the passive transfer of the RBD-specific murine antisera to the transduced mice. Subsequent challenge of the recipient transduced mice by the intra-nasal route with a clinical isolate of the MERS-CoV resulted in a significantly reduced viral load in their lungs, compared with transduced mice receiving a negative control antibody. The murine antisera used were derived from mice which had been primed sub-cutaneously with a recombinant fusion of RBD with a human IgG Fc tag (RBD-Fc), adsorbed to calcium phosphate microcrystals and then boosted by the oral route with the same fusion protein in reverse micelles. The data gained indicate that this dual-route vaccination with novel formulations of the RBD-Fc, induced systemic and mucosal anti-viral immunity with demonstrated in vitro and in vivo neutralisation capacity for clinical strains of MERS-CoV.

KW - coronavirus

KW - MERS

KW - mucosal immunity

KW - neutralising antibody

KW - novel vaccine formulation

KW - respiratory infection

KW - systemic immunity

KW - vaccination

UR - http://www.scopus.com/inward/record.url?scp=85066780154&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2019.05.074

DO - 10.1016/j.vaccine.2019.05.074

M3 - Article

VL - 37

SP - 4094

EP - 4102

JO - Vaccine

T2 - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 30

ER -

New RRC, Moore BD, Butcher W, Mahood R, Lever MS, Smither S et al. Antibody-mediated protection against MERS-CoV in the murine model. Vaccine. 2019 Jul 9;37(30):4094-4102. https://doi.org/10.1016/j.vaccine.2019.05.074